More than 1,000 eye care professionals worldwide have been using the AdaptDx® and AdaptDx Pro™ to test for impaired dark adaptation, the earliest biomarker of age-related macular degeneration. Our customers tell the story of how they’re fighting against preventable blindness by identifying AMD at its earliest stages and closely monitoring its progression.
The primary goal of every optometrist is to preserve the vision of our patients. Detecting, monitoring, and treating AMD are imperative to our mission. We can detect earlier than ever before and manage AMD by doing all we can to prevent progression to advanced stages and complications such as CNV.
The customer service education training and support that I receive from MacuLogix is second to none of any of the other companies in our profession.
The AdaptDx Pro with Theia is a huge opportunity to differentiate yourself, become more medical, and have a more successful practice as well.
When I look at the future of managing macular degeneration, I see the AdaptDx as the essential tool in AMD management just as now I see the OCT as the essential tool in managing glaucoma in its earliest stages. By finding a disease early, and intervening appropriately we have the best chance of altering the course.
The AdaptDx Pro gives us the opportunity to change the future of macular degeneration care because it allows us to screen everyone at risk and identify macular degeneration earlier. The whole objective is to reduce the number of patients losing vision from macular degeneration.
Macular degeneration is 3 times more prevalent than glaucoma and diabetic retinopathy combined. So why would I not use the AdaptDx test on everybody over the age of 50? Oh, and did I mention it helps you identify signs of subclinical AMD before you can see drusen or mottling in the eye itself?
Just like the OCT, I don't know how I practiced without the AdaptDx. Being able to diagnose AMD before we see any clinical signs and being able to monitor at the correct follow-up time for my patients that have AMD is wonderful. I felt like it was just a shot in the dark as to when I should have early AMD patients return, but now knowing their rod intercept, I can confidently say exactly when their follow-ups should be.
Prior to having the AdaptDx, I struggled with patients having complaints of night vision issues. Providing a recheck of their refractive findings and another look at their retina always came up negative. I knew this patient was providing me a legitimate complaint, but I could provide no clinical basis for this complaint. Now we test these patients using the AdaptDx and in minutes discover if their complaint is consistent with subclinical AMD. This allows me to not only diagnose their complaint, but the patient is also able to start treatment even earlier with supplementation and making lifestyle changes.
After five years of using the AdaptDx to help identify AMD at its earliest stage and then placing patients on a treatment regimen involving modifiable risk factors, I have documented many patients having improved Rod Intercept times (improved dark adaptation) and maintaining their visual acuity.
Outside of the lane, there are four essential tests that I couldn’t practice without: OCT, fundus camera, visual field, and the AdaptDx.